Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework*
作者：
关键词:
摘要:
elsevier.com
nature.com
sci-hub.se 参考文章(23)
A Ciarmiello, S Del Vecchio, P Silvestro, M I Potena, M V Carriero, R Thomas, G Botti, G D'Aiuto, M Salvatore, Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Clinical Oncology. ,vol. 16, pp. 1677- 1683 ,(1998) , 10.1200/JCO.1998.16.5.1677
J. -P. Boissel, J. -P. Collet, P. Moleur, M. Haugh, Surrogate endpoints: a basis for a rational approach. European Journal of Clinical Pharmacology. ,vol. 43, pp. 235- 244 ,(1992) , 10.1007/BF02333016
Anton Pozniak, Surrogacy in HIV-1 clinical trials. The Lancet. ,vol. 351, pp. 536- 537 ,(1998) , 10.1016/S0140-6736(98)22008-3
Stephen W. Lagakos, Surrogate Markers in AIDS: Where Are We? Where Are We Going? Annals of Internal Medicine. ,vol. 116, pp. 599- 601 ,(1992) , 10.7326/0003-4819-116-7-599
Lawrence Deyton, Importance of Surrogate Markers in Evaluation of Antiviral Therapy for HIV Infection JAMA: The Journal of the American Medical Association. ,vol. 276, pp. 159- 160 ,(1996) , 10.1001/JAMA.1996.03540020081034
John W. Blue, Wayne A. Colburn, Efficacy Measures: Surrogates or Clinical Outcomes? The Journal of Clinical Pharmacology. ,vol. 36, pp. 767- 770 ,(1996) , 10.1002/J.1552-4604.1996.TB04249.X
Paul M Ridker, None, Evaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks? Annals of Internal Medicine. ,vol. 130, pp. 933- 937 ,(1999) , 10.7326/0003-4819-130-11-199906010-00018
Jean Logan, Gene-Jack Wang, Robert R. Mac Gregor, David Schlyer, Alfred P. Wolf, Naomi Pappas, David Alexoff, Colleen Shea, Ernest Dorflinger, Lesia Kruchowy, Kisook Yoo, Enrico Fazzini, Clifford Patlak, Joanna S. Fowler, Nora D. Volkow, Slow recovery of human brain MAO B after L-Deprenyl (Selegeline) withdrawal Synapse. ,vol. 18, pp. 86- 93 ,(1994) , 10.1002/SYN.890180203
James T Macgregor, Spencer Farr, James D Tucker, John A Heddle, Raymond R Tice, Kenneth W Turteltaub, New Molecular Endpoints and Methods for Routine Toxicity Testing Fundamental and Applied Toxicology. ,vol. 26, pp. 156- 173 ,(1995) , 10.1006/FAAT.1995.1087
Robert Temple, Are surrogate markers adequate to assess cardiovascular disease drugs JAMA. ,vol. 282, pp. 790- 795 ,(1999) , 10.1001/JAMA.282.8.790